We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.16B
1-Year Est. Return 67.93%
This Fund
S&P 500
This Quarter Est. Return
-28.7%
1 Year Est. Return
+67.93%
3 Year Est. Return
-39.17%
5 Year Est. Return
-45.89%
10 Year Est. Return
–
AUM
$6.47B
AUM Growth
-$3.08B
Cap. Flow
-$5.23M
Cap. Flow %
-0.08%
Top 10 Hldgs %
99%
Holding
13
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
DNLI icon
Denali Therapeutics
DNLI
+$5.23M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$21.5B
$4.47B 69.04%
17,581,016
– –
SANA icon
2
Sana Biotechnology
SANA
$885M
$530M 8.19%
34,239,018
– –
RUBY
3
DELISTED
Rubius Therapeutics, Inc
RUBY
$373M 5.76%
38,506,526
– –
OMGA
4
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$293M 4.54%
25,902,269
– –
FHTX icon
5
Foghorn Therapeutics
FHTX
$285M
$290M 4.48%
12,674,120
– –
EVLO
6
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$140M 2.16%
1,151,503
– –
MCRB icon
7
Seres Therapeutics
MCRB
$48.1M
$120M 1.85%
718,940
– –
DNLI icon
8
Denali Therapeutics
DNLI
$3.67B
$117M 1.81%
2,619,968
-110,295
-4% -$5.23M
KLDO
9
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$46.8M 0.72%
19,575,710
– –
CDAK
10
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$29M 0.45%
2,607,303
– –
SGTX
11
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$28.6M 0.44%
797,721
– –
AXLA
12
DELISTED
Axcella Health Inc. Common Stock
AXLA
$26.2M 0.41%
501,937
– –
SYRS
13
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$9.58M 0.15%
293,849
– –

Similar funds

AC
AltraVue Capital Bellevue, Washington $1.16B AUM 46.45% 1-Year Est. Return
BI
Bramshill Investments Naples, Florida $1.16B AUM 0.86% 1-Year Est. Return
SCP
Sandhill Capital Partners Buffalo, New York $1.16B AUM 12.37% 1-Year Est. Return
SFG
SNS Financial Group Minneapolis, Minnesota $1.16B AUM 13.88% 1-Year Est. Return
GAB
German American Bancorp Jasper, Indiana $1.16B AUM 25.7% 1-Year Est. Return
AMI
Amica Mutual Insurance Providence, Rhode Island $1.16B AUM 21.34% 1-Year Est. Return
FFP
FourThought Financial Partners Venice, Florida $1.16B AUM 24.95% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Flagship Pioneering's Q4 2021 Portfolio in Review

As of Q4 2021, Flagship Pioneering held 13 positions worth $6.47B, down 32% from $9.55B the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Trading was light in Q4 2021: portfolio turnover was 0%. Flagship Pioneering opened no new positions and made no exits, leaving the 13-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Flagship Pioneering's biggest Q4 2021 reduction was Denali Therapeutics, cutting an estimated $5.23M.
  • Flagship Pioneering's ten largest holdings make up 99% of its $6.47B portfolio in Q4 2021.
  • Flagship Pioneering opened 0 new positions and closed 0 in Q4 2021.
  • Flagship Pioneering's portfolio value fell 32% quarter-over-quarter to $6.47B.

Based on Flagship Pioneering's 13F filing for Q4 2021, filed 14 Feb 2022.